NIOX Competitors and Similar CompaniesClear all
NIOX's competitors and similar companies include Affimed N.V., Zogenix, Durect and Sucampo Pharmaceuticals.
 NIOX NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies |  Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. |  Zogenix Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology. |  Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. |  Sucampo Pharmaceuticals Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis. | |
Founding Date | Founding Date 2006 | Founding Date 2000 | Founding Date 2006 | Founding Date N/A | Founding Date 1996 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Morrisville, US HQ Bad Homburg Vor Der Höhe, DE Uppsala, SE Morrisville, US | Locations Heidelberg, DE HQ | Locations Emeryville, US HQ Maidenhead, GB | Locations Cupertino, US HQ | Locations Rockville, US HQ Chiyoda, JP Chuo Ward, JP Kita Ward, JP Sanda Shi, JP Zug, CH Milton, GB |
Employees | Employees 91 | Employees 76 | Employees 743% increase | Employees 902% increase | Employees 37 |
Valuation ($) | Valuation ($) 340.9 m | Valuation ($) 52.5 m | Valuation ($) N/A | Valuation ($) 45.3 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) £48.7m (FY, 2025) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $81.7m (FY, 2021) | Revenue (est.) $2m (FY, 2024) | Revenue (est.) $230.1m (FY, 2016) |
Cost of goods | Cost of goods £11.1m (FY, 2025) | Cost of goods N/A | Cost of goods $4.8m (FY, 2021) | Cost of goods $78k (FY, 2024) | Cost of goods $76m (FY, 2016) |
Gross profit | Gross profit £38.2m (FY, 2025) | Gross profit €13m (FY, 2023) | Gross profit N/A | Gross profit $2m (FY, 2024) | Gross profit $154.1m (FY, 2016) |
Net income | Net income £7m (FY, 2025) | Net income (€105.9m) (FY, 2023) | Net income ($227.4m) (FY, 2021) | Net income ($8.3m) (FY, 2024) | Net income $18.5m (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 122.8m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 20m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Affimed N.V.
HQ
Heidelberg, DE
Employees
76
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View companyZogenix
HQ
Emeryville, US
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
View companyDurect
HQ
Cupertino, US
Employees
90↑ 2% increase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
View companySucampo Pharmaceuticals
HQ
Rockville, US
Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines based on prostones, to meet the major unmet medical needs of patients on a global basis.
View company